SpaceOAR gel use during prostate cancer radiation
Part of Cancer, Kidney & urinary clinical trials.
This study is a registry that collects information from people receiving standard care with a gel called SpaceOAR during radiation therapy for prostate cancer. It helps doctors learn more about how the gel works in routine practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being treated for prostate cancer with the goal of curing it.
- Your treatment plan includes using the SpaceOAR gel (a spacer placed between the prostate and rectum to reduce side effects).
- You are 18 years old or older.
- You can give informed consent (either verbally over the phone in the UK, or by signing a form in France).
- You are covered by a social security scheme if you are in France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether placing a soft gel spacer near the rectum can make “salvage” prostate radiation safer and more tolerable when prostate cancer comes back locally. It may help reduce side effects by creating extra space between the rectum and the radiation area.
This trial tests how well a rectal spacer works when you get proton beam therapy for prostate cancer. The spacer is a gel placed between your prostate and rectum to protect healthy tissue.
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
This study tests a precise type of radiation (stereotactic radiotherapy) for men with early-stage prostate cancer. It aims to see if using custom radiation beams improves outcomes while reducing side effects.
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
Hear when a new Prostate Cancer Patients Treated by Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.